Introduction to and Organization of the Laboratory

Hanmi Fine Chemical is striving to develop into a global Active Pharmaceutical Ingredient corporation with an unending passion for R&D.

Unending passion for R&D
Hanmi Fine Chemical is leading the development of Active Pharmaceutical Ingredients with the highest level of R&D investment among all other companies in the same industry (higher than 7% of sales). Since the development of Cefotaxime, a Cephalosporin antibiotic, for the first time in Korea in 1984, we have exported our technologies including Ceftriaxone (1987) and Gemcitabine (2005) to leading global pharmaceutical companies. We will continue to grow into a leading, globally-active pharmaceutical ingredient development company that contributes to the promotion of human health and a healthy society through continuous creation, innovation, and active investment in small molecules, peptides, and oligonucleotide pharmaceuticals.

Introduction to and Organization of the Laboratory

Laboratory
  1. 01 Synthesis Research
    • Research of oligonucleotide synthesis method
    • Research of peptide synthesis through the development of original technology
    • Research of PEG linker/PEGylation synthesis method
    • Research on the purification process of bio-based active pharmaceutical ingredients
    • Research of active pharmaceutical ingredient(API) synthesis method
    • Process development (scale up/regulatory supporting research)
  2. 02 Analytical Research
    • Analytical method development by A-QbD
    • Research for Impurity profile and reference standard
    • Genotoxic impurity study and in-silico study
    • Preparation of CTD data
  3. 03 Technical Sales
    • Based on our own core technologies, we have conducted sales for Japanese-specific Cephalosporin APIs, General APIs, and new technology development.
  4. 04 CDMO
    • Coordination of the entire CDMO work of Hanmi Fine Chemical
    • Conducting of domestic and overseas CDMO business
    • Possession of many collaborative experiences with overseas big pharma organizations
    • Conducting scale-ups after process development
    • cGMP production and licensing for clinical sample manufacturing and preparation of CTD documents for registration
  5. 05 New Business Planning
    • Explore the latest and most promising technologies in the bio field, such as market status, patent status, and licensing trends
    • Databasing of discovered ideas and segmentation of mid- to long-term plans
    • Review and discover new projects or new action plans by analyzing data and generating data for decision-making